Want to know the trends shaping the future of gene therapy manufacturing? Project Farma’s EVP, Tony Khoury and Aruvant CTO, Palani Palianappan sat down with The Business of Biotech podcast for a deep dive into the role of artificial intelligence in the discovery of AAV capsids that can avoid the immune system, the growth of non-viral vectors, the scale up advantages of suspension technologies versus adherence, the evolution of the regulatory environment, manufacturing capacity and talent constraints, and much, much more. Listen to Episode 61, “The Future of Gene Therapy Manufacturing”.
To listen to this on-demand podcast, click here.
